Company: RNAC
Filing Date: 2025-01-08
Form Type: 424B7
Source: 0001140361-25-000634
Chunk: 1

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-01-08
Form: 424B7
Chunk 1
---
 or quoted at the time of sale, on the over-the-counter market, in one or more transactions otherwise than on these exchanges or systems, such as privately negotiated transactions, or using a combination of these methods, and at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale, or at negotiated prices. See the disclosure under the heading “ Plan of Distribution ” elsewhere in this prospectus for more information about how the Selling Stockholders may sell or otherwise dispose of their Resale Shares hereunder.

The Selling Stockholders may sell any, all or none of the securities offered by this prospectus and we do not know when or in what amount the Selling Stockholders may sell their Resale Shares hereunder following the effective date of the registration statement of which this prospectus forms a part.

The Selling Securityholders may be deemed to be “underwriters” within the meaning of the Securities Act of 1933, as amended, or the Securities Act, of the Resale Shares that they are offering pursuant to this prospectus.

You should carefully read this prospectus and any applicable prospectus supplement before you invest in any of the securities being offered.

Our Common Stock is traded on the Nasdaq Global Market under the symbol “RNAC.” On January 7, 2025, the last reported sale price for our Common Stock was $17.16 per share.

Investing in our securities involves a high degree of risk. Before investing in our securities, you should carefully consider the risks and uncertainties described under the caption “**

#### Risk Factors

#### ” beginning on page

#### 9
**of this prospectus and any similar section contained in the applicable prospectus supplement and in any free writing prospectus we have authorized for use in connection with a specific offering, and under similar headings in the documents incorporated by reference into this prospectus.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.**

#### The date of this prospectus is January 8, 2025.
TABLE OF CONTENTS

TABLE OF CONTENTS

| ABOUT THIS PROSPECTUS                                |     |  1 |
| CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS |     |  2 |
| WHERE YOU CAN FIND MORE INFORMATION                  |     |  4 |
| INCORPORATION BY REFERENCE                           |     |